Home

Treatment satisfaction of patients with neovascular age-related macular degeneration receiving antiangiogenic therapy

Written by Bobykin E.V., Korotkikh S.A., Nerus I.A., Morozova O.V.

  UDK: 617.736–085.216.84–071.1 | DOI: 10.17238/PmJ1609-1175.2019.2.14–18 | Pages: 14–18 | Full text PDF | Open PDF 

Annotation:

Objective: clinical testing of original ophthalmologic survey to assess treatment satisfaction (TS) in patients getting antiangiogenic therapy for neovascular macular diseases.
Methods. Tested group consisted of 38 people (31 women, 9 men) aged from 51 to 93 y.o. with neovascular age-related macular degeneration, they got antiangiogenic therapy (ranibizumab, aflibercept). Ptients were divided into subgroups with high (n=20) and low (n=18) compliance levels. We conducted a single survey with a questionnaire which included standard validated questionnaire on treatment satisfaction in macular diseases (MacTSQ) and questions assessing aspects of antiangiogenic therapy composed by authors.
Results. We determined significant direct correlation between and high level of compliance, and patients with high level of treatment adherence were more willing to return to therapy and were less dependent on outside help. The survey took 7 minutes in average. Despite elderly age patients did not struggle with understanding of questions and answering them.
Conclusions. We developed a method of TS level detection in patients with macular pathology who received antiangiogenic therapy. The method is based on scoring the answers to survey questions. The analysis of survey results can contribute to effectiveness of the therapy due to customized dosing schedule.

Links to authors:

E.V. Bobykin, S.A. Korotkikh, I.A. Nerus, O.V. Morozova
Ural State Medical University (3 Repina St. Yekaterinburg 620014 Russian Federation)


1. Kunickaya S.V. To the problem of public satisfaction with medical care // Questions of Organization and Informatization of Health Care. 2006. No. 3. P. 33–36.
2. Malyshev A.V., Trubilin V.N., Makkaeva S.M. [et al.]. The study of the quality of life of patients during ophthalmosurgical interventions // Modern problems of science and education. 2014. No. 5. URL: http://science-education.ru/ru/article/view?id=14261 (date of access: 13.02.2019).
3. Novik A.A., Ionova T.I., Kajnd P. The concept of the study of quality of life in medicine. St Petersburg: EHLBI, 1999. 139 p.
4. Bobykin E., Korotkikh S., Nerus I. Evaluation of quality of life and treatment satisfaction of patients receiving anti-VEGF therapy // Ophthalmic Research. 2018. Vol. 60 (Suppl. 1). P. 4.
5. Brose L.S., Bradley C. Psychometric development of the retinopathy treatment satisfaction questionnaire (RetTSQ) // Psychol. Health Med. 2009. Vol. 14, No. 6. P. 740–754.
6. Dubuc S., Wittich W., Gomolin J.E. [et al.]. Beyond visual acuity: functional outcome and patient satisfaction following treatment for age-related macular degeneration // Can. J. Ophthalmol. 2009. Vol. 44, No. 6. P. 680–685.
7. Gohil R., Crosby-Nwaobi R., Forbes A. [et al.]. Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting // Patient Preference and Adherence. 2016. No. 10. P. 949–955.
8. Kosmidis P. Quality of life as a new end point // Chest. 1996. Vol. 109 (Suppl. 5). P. 110–121.
9. Mitchell J., Bradley C. Design and development of the MacTSQ measure of satisfaction with treatment for macular conditions used within the IVAN trial // J. Patient Rep. Outcomes. 2018. Vol. 2. Art. 5. doi: 10.1186/s41687-018-0031-z
10. Sherwood M.B., Garcia-Siekavizza A., Meltzer M.I., [et al.]. Glaucoma’s impact on quality of life and its relation to clinical indicators. A pilot study // Ophthalmology. 1998. Vol. 105, No. 3. P. 561–566.
11. Williams R.A., Brody B.L., Thomas R.G. [et al.]. The psychosocial impact of macular degeneration // Arch. Ophthalmol. 1998. Vol. 116. P. 514–520.

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.